Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 875-882

  Moss, John A ^a   Malone, Amanda M ^b   Smith, Thomas J ^a,b,c   Kennedy, Sean ^a   Kopin, Etana ^b   Nguyen, Cali ^a,b   Gilman, Josh ^b   Butkyavichene, Irina ^b   Vincent, Kathleen L ^d   Motamedi, Massoud ^d   Friend, David R ^e   Clark, Meredith R ^e   Baum, Marc M ^a  

^a OAK CREST INSTITUTE OF SCIENCE   (United States)

^b Auritec Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; MICROBICIDE; TENOFOVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DEVICE SAFETY; DISEASE ASSOCIATION; DRUG DELIVERY SYSTEM; EXPERIMENTAL ANIMAL; FEMALE; HERPES SIMPLEX; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; SAMPLE; SHEEP; SLOW DRUG RELEASE; SUSTAINED DRUG RELEASE; VAGINA; VAGINA MUCOSA; VAGINA RING; VAGINA SECRETION;

ACYCLOVIR; ADENINE; ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; ORGANOPHOSPHONATES; RABBITS; SEXUALLY TRANSMITTED DISEASES, VIRAL; TREATMENT OUTCOME;

EID: 84856071435     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05662-11     Document Type: Article

References (47)

1. Reference deleted.
2. American Congress of Obstetricians and Gynecologists. 2000. Practice bulletin, management of anovulatory bleeding, clinical management guidelines for obstetrician-gynecologists, p. 1049-1056. ACOG 2009 compendium, vol. 14. American Congress of Obstetricians and Gynecologists, Washington, DC.
3. Anglewicz PA, Bignami-Van Assche S, Clark S, Mkandawire J. 2010. HIV risk among currently married couples in rural Malawi: what do spouses know about each other? AIDS Behav. 14:103-112.
4. Antoniou T, Park Wyllie LY, Tseng AL. 2003. Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection. Pharmacotherapy 23:29-43. (Pubitemid 36077364)
5. Barberini F, Desantis F, Correr S, Motta PM. 1992. The mucosa of the rabbit vagina - a proposed experimental model for correlated morphofunctional studies in humans. Eur. J. Obstet. Gynecol. Reprod. Biol. 44:221-227.
6. Cairns G. 26 February 2008, posting date. Microbicides 2008: accurate adherence reporting essential for microbicide trials. NAM Publications, London, United Kingdom. http://www.aidsmap.com/Microbicides-2008-Accurate-adherence- reporting-essential-for-microbicide-trials/page/1429709/.
7. Carr EB. 1953. The development of the rabbit vagina. J. Anat. 87:423-431.
8. Castle PE, Hoen TE, Whaley KJ, Cone RA. 1998. Contraceptive testing of vaginal agents in rabbits. Contraception 58:51-60. (Pubitemid 28402305)
9. Chien YW, et al. 1975. Controlled drug release from polymeric delivery devices. 3. In vitro-in vivo correlation for intravaginal release of ethynodiol diacetate from silicone devices in rabbits. J. Pharm. Sci. 64:1776-1781.
10. Clark MR, et al. 2011. Pharmacokinetics of UC781-loaded intravaginal ring segments in rabbits: a comparison of polymer matrices. Drug Deliv. Trans. Res. 1:238-246.
11. Cole AM, et al. 2010. The formulated microbicide RC-101 was safe and antivirally active following intravaginal application in pigtailed macaques. PLoS One 5:e15111.
12. Cumming G, Fidler F, Vaux DL. 2007. Error bars in experimental biology. J. Cell Biol. 177:7-11. (Pubitemid 46588396)
13. Cunningham FG, et al. 1997. Williams obstetrics, 20th ed. Appleton &Lange, Stamford, CT.
14. De Clercq E. 2004. Antiviral drugs in current clinical use. J. Clin. Virol. 30:115-133. (Pubitemid 38582018)
15. Dunkle KL, et al. 2008. New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet 371:2183-2191. (Pubitemid 351885039)
16. Eyawo O, et al. 2010. HIV status in discordant couples in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect. Dis. 10:770-777.
17. Fleming DT, et al. 1997. Herpes simplex virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med. 337:1105-1111. (Pubitemid 27444100)
18. Freeman EE, et al. 2007. Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics. Sex. Transm. Infect. 83:I17-I24. (Pubitemid 47242468)
19. Freeman EE, et al. 2006. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20:73-83. (Pubitemid 41818117)
20. Geonnotti AR, Katz DF. 2010. Compartmental transport model of microbicide delivery by an intravaginal ring. J. Pharm. Sci. 99:3514-3521.
21. Guthrie BL, et al. 2009. Sexually transmitted infections among HIV-1-discordant couples. PLoS One 4:e8276.
22. Hayes S, Dunne A, Smart T, Davis J. 2004. Interpretation and optimization of the dissolution specifications for a modified release product with an in vivo-in vitro correlation (IVIVC). J. Pharm. Sci. 93:571-581. (Pubitemid 38332290)
23. Karim QA, et al. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168-1174.
24. Karim SSA, Kashuba ADM, Werner L, Karim QA. 2011. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 378:279-281.
25. Lerbaek A, et al. 2004. Tenofovir treatment in an unselected cohort of highly antiretroviral experienced HIV positive patients. Scand. J. Infect. Dis. 36:280-286. (Pubitemid 38714180)
26. London S. 2008. Most heterosexual HIV transmission in urban Rwanda and Zambia occurs in married or cohabiting couples. Int. Fam. Plan. Perspect. 34:146.
27. Malcolm RK, Edwards KL, Kiser P, Romano J, Smith TJ. 2010. Advances in microbicide vaginal rings. Antiviral Res. 88:S30-S39.
28. Mbopi-Keou FX, et al. 2000. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J. Infect. Dis. 182:1090-1096.
29. National Academy Press. 1996. The guide for the care and use of laboratory animals. Institute of Laboratory Animal Resources, National Academy Press, Washington, DC.
30. Nel A, et al. 2009. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J. AIDS 51:416-423.
31. Owen DH, Katz DF. 1999. A vaginal fluid simulant. Contraception 59:91-95. (Pubitemid 29244754)
32. Parikh UM, et al. 2009. Complete protection from repeated vaginal simian-human Immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J. Virol. 83:10358-10365.
33. Promadej-Lanier N, et al. 2009. Development and evaluation of a vaginal ring device for sustained delivery of HIV microbicides to non-human primates. J. Med. Primatol. 38:263-271.
34. Renzi C, et al. 2003. Herpes simplex virus type 2 infection as a risk factor for human immunodeficiency virus acquisition in men who have sex with men. J. Infect. Dis. 187:19-25. (Pubitemid 36034467)
35. Reynolds SJ, et al. 2003. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J. Infect. Dis. 187:1513-1521. (Pubitemid 36578957)
36. Romano J, et al. 2009. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res. Hum. Retrovir. 25:483-488.
37. Saxena BB, et al. 2009. Sustained release of microbicides by newly engineered vaginal rings. AIDS 23:917-922.
38. Smith DJ, et al. 2008. An evaluation of intravaginal rings as a potential HIV prevention device in urban Kenya: behaviors and attitudes that might influence uptake within a high-risk population. J. Women's Health 17:1025-1034.
39. UNAIDS. 2008. 2008 report on the global AIDS epidemic. UNAIDS, Geneva, Switzerland.
40. US Department of Health Human Services. 2010. Use of contraception in the United States 1982-2008, vital and health statistics. U.S. Department of Health and Human Services, Washington, DC.
41. Valenta C. 2005. The use of mucoadhesive polymers in vaginal delivery. Adv. Drug Deliv. Rev. 57:1692-1712. (Pubitemid 41444256)
42. Vincent KL, et al. 2009. High resolution imaging of epithelial injury in the sheep cervicovaginal tract: a promising model for testing safety of candidate microbicides. Sex. Transm. Dis. 36:312-318.
43. Voelker R. 2005. Women shoulder growing HIV/AIDS burden. JAMA 293:281-282. (Pubitemid 40116070)
44. Wald A, Link K. 2002. Risk of human immunodeficiency virus infection in herpes simplex virus type 2 seropositive persons: a meta-analysis. J. Infect. Dis. 185:45-52. (Pubitemid 34043015)
45. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. HIV/AIDS Department, World Health Organization, Geneva, Switzerland.
46. Xu FJ, et al. 2006. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296:964-973.
47. Yoo JW, Lee CH. 2006. Drug delivery systems for hormone therapy. J. Control. Release 112:1-14.